{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70759"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Survodutide?<\/h3>\n

Survodutide<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 research it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n2230198-02-2 (survodutide; commonly cited)<\/td>\n<\/tr>\n
Type<\/strong><\/td>\nLong-acting dual GLP-1 \/ glucagon receptor co-agonist (acylated synthetic peptide; Boehringer Ingelheim BI 456906; co-developed with Zealand Pharma)<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n~3,800 Da (with fatty-acid acylation; mature peptide form)<\/td>\n<\/tr>\n
Structure<\/strong><\/td>\n29-amino-acid synthetic peptide co-agonist with engineered Aib substitutions for DPP-4 resistance and a fatty-diacid acyl chain attached at a lysine residue via a \u03b3-Glu linker. Substantially shorter than oxyntomodulin-derived dual agonists (mazdutide ~39 aa) while preserving balanced dual GLP-1\/glucagon receptor activity.<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (wit tot off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows. Acylated peptides may dissolve more slowly \u2014 allow extra equilibration time.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Survodutide?<\/h2>\n

Survodutide<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist research programme, alongside the parallel programmes that produced mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation.<\/p>\n

Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing.<\/p>\n

The current clinical signature of survodutide is the striking MASH (metabolic-dysfunction-associated steatohepatitis) liver-fibrosis effect<\/strong> reported in the Phase 2 trial \u2014 an outcome that distinguished it from other dual and triple agonists with similar body-weight effects. Phase 2 obesity data showed body-weight reductions of approximately 19% at 4.8\u00a0mg weekly over 46 weeks, putting survodutide in the same effect-size tier as tirzepatide and at the boundary of triple-agonist retatrutide. Survodutide is currently in Phase 3 trials for obesity (SURMOUNT-style trial design) and MASH. Survodutide is niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The research-grade survodutide sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration. For the sibling dual GLP-1\/glucagon co-agonist, see our Mazdutide<\/a> product page; for the triple-agonist that adds GIP, see Retatrutide<\/a>.<\/p>\n

Mechanism of Action \u2014 Dual GLP-1 \/ Glucagon Receptor Co-Agonism with Hepatic Emphasis<\/h2>\n

What makes survodutide mechanistically distinctive among dual-agonist metabolic peptides is the relatively balanced GLP-1-to-glucagon potency ratio<\/strong> that produces both substantial energy-expenditure effects (the glucagon arm) and the canonical GLP-1 satiety\/glycaemic effects, with a particular emphasis on hepatic outcomes:<\/p>\n